Literature DB >> 28138972

Glaucarubulone glucoside from Castela macrophylla suppresses MCF-7 breast cancer cell growth and attenuates benzo[a]pyrene-mediated CYP1A gene induction.

Simone A M Badal1,2, Malyn M Asuncion Valenzuela3, Dain Zylstra4, George Huang5, Pallavi Vendantam5, Sheena Francis1, Ashley Quitugua4, Louisa H Amis3, Willie Davis3,4, Tzuen-Rong J Tzeng5, Helen Jacobs6, David J Gangemi5, Greg Raner7,8, Leah Rowland3, Jonathan Wooten3, Petreena Campbell3, Eileen Brantley3,4,9, Rupika Delgoda1.   

Abstract

Quassinoids often exhibit antioxidant and antiproliferative activity. Emerging evidence suggests that these natural metabolites also display chemopreventive actions. In this study, we investigated the potential for the quassinoid glaucarubulone glucoside (Gg), isolated from the endemic Jamaican plant Castela macrophylla (Simaroubaceae), to display potent cytotoxicity and inhibit human cytochrome P450s (CYPs), particularly CYP1A enzymes, known to convert polyaromatic hydrocarbons into carcinogenic metabolites. Gg reduced the viability of MCF-7 breast adenocarcinoma cells (IC50 = 121 nm) to a greater extent than standard of care anticancer agents 5-fluorouracil, tamoxifen (IC50 >10 μm) and the tamoxifen metabolite 4-hydroxytamoxifen (IC50 = 2.6 μm), yet was not cytotoxic to non-tumorigenic MCF-10A breast epithelial cells. Additionally, Gg induced MCF-7 breast cancer cell death. Gg blocked increases in reactive oxygen species in MCF-10A cells mediated by the polyaromatic hydrocarbon benzo[a]pyrene (B[a]P) metabolite B[a]P 1,6-quinone, yet downregulated the expression of genes that promote antioxidant activity in MCF-7 cells. This implies that Gg exhibits antioxidant and cytoprotective actions in non-tumorigenic breast epithelial cells and pro-oxidant, cytotoxic actions in breast cancer cells. Furthermore, Gg inhibited the activities of human CYP1A according to non-competitive kinetics and attenuated the ability of B[a]P to induce CYP1A gene expression in MCF-7 cells. These data indicate that Gg selectively suppresses MCF-7 breast cancer cell growth without impacting non-tumorigenic breast epithelial cells and blocks B[a]P-mediated CYP1A induction. Taken together, our data provide a rationale for further investigations of Gg and similar plant isolates as potential agents to treat and prevent breast cancer.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  breast cancer; chemoprevention; cytochrome P450; cytotoxicity; natural product

Mesh:

Substances:

Year:  2017        PMID: 28138972      PMCID: PMC5435539          DOI: 10.1002/jat.3436

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  57 in total

1.  Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent.

Authors:  Yoshihide Usami; Kyoko Nakagawa-Goto; Jing-Yu Lang; Yoon Kim; Chin-Yu Lai; Masuo Goto; Nobuko Sakurai; Masahiko Taniguchi; Toshiyuki Akiyama; Susan L Morris-Natschke; Kenneth F Bastow; Gordon Cragg; David J Newman; Mihoyo Fujitake; Koichi Takeya; Mien-Chie Hung; Eva Y-H P Lee; Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2010-09-24       Impact factor: 4.050

2.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

Authors:  C L Crespi; V P Miller; B W Penman
Journal:  Anal Biochem       Date:  1997-05-15       Impact factor: 3.365

3.  Significant inhibitory impact of dibenzyl trisulfide and extracts of Petiveria alliacea on the activities of major drug-metabolizing enzymes in vitro: An assessment of the potential for medicinal plant-drug interactions.

Authors:  J Murray; D Picking; A Lamm; J McKenzie; S Hartley; C Watson; L Williams; H Lowe; R Delgoda
Journal:  Fitoterapia       Date:  2016-04-20       Impact factor: 2.882

Review 4.  Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action.

Authors:  William M Baird; Louisa A Hooven; Brinda Mahadevan
Journal:  Environ Mol Mutagen       Date:  2005 Mar-Apr       Impact factor: 3.216

Review 5.  Environmental and chemical carcinogenesis.

Authors:  Gerald N Wogan; Stephen S Hecht; James S Felton; Allan H Conney; Lawrence A Loeb
Journal:  Semin Cancer Biol       Date:  2004-12       Impact factor: 15.707

6.  Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells.

Authors:  Andrew D Burdick; John W Davis; Ke Jian Liu; Laurie G Hudson; Honglian Shi; Michael L Monske; Scott W Burchiel
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

7.  Developing a high-throughput system for the screening of cytochrome P450 1A1--inhibitory polyphenols.

Authors:  Hau Yi Leung; Yun Wang; Ho Yee Chan; Lai K Leung
Journal:  Toxicol In Vitro       Date:  2007-04-27       Impact factor: 3.500

8.  Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

Authors:  David M Stresser; Marc I Broudy; Thuy Ho; Catherine E Cargill; Andrew P Blanchard; Raman Sharma; Andre A Dandeneau; Joseph J Goodwin; Stephanie D Turner; John C L Erve; Christopher J Patten; Shangara S Dehal; Charles L Crespi
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

9.  Grape Seed Proanthocyanidin Extract Ameliorates Diabetic Bladder Dysfunction via the Activation of the Nrf2 Pathway.

Authors:  Shouzhen Chen; Yaofeng Zhu; Zhifeng Liu; Zhaoyun Gao; Baoying Li; Dongqing Zhang; Zhaocun Zhang; Xuewen Jiang; Zhengfang Liu; Lingquan Meng; Yue Yang; Benkang Shi
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

10.  Menadione Suppresses Benzo(α)pyrene-Induced Activation of Cytochromes P450 1A: Insights into a Possible Molecular Mechanism.

Authors:  Yulia A Sidorova; Maria L Perepechaeva; Elena N Pivovarova; Arkady L Markel; Vyacheslav V Lyakhovich; Alevtina Y Grishanova
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.